JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Predictive diagnostic value of mean platelet volume to platelet count and neutrophil to lymphocyte ratios in the gray zone of prostate cancer with tPSA between 4 to 10 ng/mL

  • 0Xiangtan Central Hospital, Xiangtan, Hunan, China.
Frontiers in Oncology +

|

October 29, 2024

|

October 29, 2024

View abstract on PubMed

Summary

This summary is machine-generated.

The Mean Platelet Volume to Platelet Count Ratio (PVI) and Neutrophil-to-Lymphocyte Ratio (NLR) can help diagnose prostate cancer in the PSA gray zone. Utilizing these markers improves early prostate cancer screening accuracy.

Area Of Science

  • Urology
  • Oncology
  • Hematology

Background

  • The prostate-specific antigen (PSA) gray zone presents diagnostic challenges for differentiating prostate cancer (PCa) from benign prostatic hyperplasia (BPH).
  • Biomarkers are needed to improve diagnostic accuracy in this ambiguous range.

Purpose Of The Study

  • To evaluate the predictive diagnostic value of the Mean Platelet Volume to Platelet Count Ratio (PVI) and Neutrophil-to-Lymphocyte Ratio (NLR) in the tPSA gray zone.
  • To assess the utility of PVI and NLR in improving early prostate cancer screening.

Main Methods

  • A retrospective study included 65 PCa patients and 52 BPH patients who underwent transperineal prostate biopsy.
  • Logistic regression and Receiver Operating Characteristic (ROC) curve analyses were employed to determine the predictive value of PVI and NLR.

Main Results

  • Both PVI (OR=2.03) and NLR (OR=0.32) were identified as independent predictors for PCa in the tPSA gray zone.
  • PVI demonstrated an Area Under the Curve (AUC) of 0.70, while NLR showed an AUC of 0.76, indicating significant diagnostic capability.
  • Calibration curves confirmed good predictive performance of the developed nomogram model.

Conclusions

  • PVI and NLR possess significant predictive diagnostic value for PCa within the tPSA gray zone.
  • The combined use of PVI and NLR can enhance the accuracy of early prostate cancer screening in the PSA gray zone.

Keywords: